Overview A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. Status: Terminated Trial end date: 2014-04-01 Target enrollment: Participant gender: Summary Response rates. Changes in tumor blood flow. Phase: Phase 2 Details Lead Sponsor: Sidney Kimmel Comprehensive Cancer CenterSidney Kimmel Comprehensive Cancer Center at Johns HopkinsTreatments: CisplatinGemcitabineHydroxyitraconazoleItraconazole